NF-KappaB Inhibitor alpha

• 

  Subject Areas on Research

  • Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. 
  • Canonical transient receptor potential 3 channels activate NF-κB to mediate allergic airway disease via PKC-α/IκB-α and calcineurin/IκB-β pathways. 
  • Characterization of COMMD protein-protein interactions in NF-kappaB signalling. 
  • Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase. 
  • Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. 
  • Copper is a potent inhibitor of both the canonical and non-canonical NFκB pathways. 
  • Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation. 
  • Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. 
  • Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells. 
  • Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). 
  • Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. 
  • Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. 
  • Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. 
  • Gamma-aminobutyric acid inhibits synergistic interleukin-6 release but not transcriptional activation in astrocytoma cells. 
  • Inhibition of NF-kappa B by S-nitrosylation. 
  • Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. 
  • Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. 
  • Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. 
  • NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. 
  • NO inhibits hyperoxia-induced NF-κB activation in neonatal pulmonary microvascular endothelial cells. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • Nuclear factor-kappaB mediates Kupffer cell apoptosis through transcriptional activation of Fas/FasL. 
  • Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. 
  • Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. 
  • Regulation of NFkappaB in hepatic ischemic preconditioning. 
  • RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts. 
  • Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. 
  • Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. 
  • TNFR2 interposes the proliferative and NF-κB-mediated inflammatory response by podocytes to TNF-α. 
  • The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. 
  • The multisubunit IkappaB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IkappaB alpha. 
  • Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes. 
  • beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha.